| ABSTRACT Objective: This paper analyzes the current situation, effect and main problems of centralized drug procurement in China’s public medical institutions, and provides a reference for further improving the centralized drug procurement policy. Methods:To search the databases of CNKI, WanFang Data and VIP from June 2015 to December 2018 with the keywords of “drug procurement, public hospital, medical institution". The literature was filtered according to inclusion and exclusion criteria, and its characteristics, current situation, main resultsand prominent problems were quantitatively and qualitatively analyzed by means of composition ratio and other indicators. Results:A total of 37 papers included in this study believe that the implementation of centralized drug procurement is mainly conducive to reducing drug price (29.7%) and ensuring drug supply (13.5%). However, the existing problems mainly focus on “quantity price decoupling”(18.9%), “secondary bargaining”(16.2%), drug supply shortage (8.1%), virtual high and virtual low price (21.6%), late payment (8.1%), and group parchasing organization（GPO） lack of uniform specifications (5.4%). Conclusion:The main body of centralized drug procurement is out of position. In order to adapt to the changes of policy and the reform of “Three Medical linkage” in the new era, it is urgent to implement the policy of “purchasing with quantity” and improve the comprehensive supervision and drug quality evaluation system. |
